Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesChange in Working CapitalDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MDxHealth (MDXH) Other financing activities (2021 - 2025)

Historic Other financing activities for MDxHealth (MDXH) over the last 4 years, with Q3 2025 value amounting to -$2.6 million.

  • MDxHealth's Other financing activities fell 3033.32% to -$2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$9.0 million, marking a year-over-year decrease of 22458.42%. This contributed to the annual value of -$6.7 million for FY2024, which is 8565.1% down from last year.
  • Latest data reveals that MDxHealth reported Other financing activities of -$2.6 million as of Q3 2025, which was down 3033.32% from -$2.6 million recorded in Q2 2025.
  • In the past 5 years, MDxHealth's Other financing activities registered a high of -$240000.0 during Q1 2022, and its lowest value of -$2.6 million during Q3 2025.
  • For the 4-year period, MDxHealth's Other financing activities averaged around -$1.3 million, with its median value being -$1.8 million (2024).
  • Data for MDxHealth's Other financing activities shows a peak YoY increase of 3033.32% (in 2025) and a maximum YoY decrease of 3033.32% (in 2025) over the last 5 years.
  • Over the past 4 years, MDxHealth's Other financing activities (Quarter) stood at -$244000.0 in 2021, then dropped by 11.07% to -$271000.0 in 2022, then crashed by 565.31% to -$1.8 million in 2024, then tumbled by 45.37% to -$2.6 million in 2025.
  • Its Other financing activities was -$2.6 million in Q3 2025, compared to -$2.6 million in Q2 2025 and -$2.0 million in Q1 2025.